5VYF

Structure of single chain Fel d 1 bound to a neutralizing antibody


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.9 Å
  • R-Value Free: 0.259 
  • R-Value Work: 0.225 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement.

Orengo, J.M.Radin, A.R.Kamat, V.Badithe, A.Ben, L.H.Bennett, B.L.Zhong, S.Birchard, D.Limnander, A.Rafique, A.Bautista, J.Kostic, A.Newell, D.Duan, X.Franklin, M.C.Olson, W.Huang, T.Gandhi, N.A.Lipsich, L.Stahl, N.Papadopoulos, N.J.Murphy, A.J.Yancopoulos, G.D.

(2018) Nat Commun 9: 1421-1421

  • DOI: 10.1038/s41467-018-03636-8

  • PubMed Abstract: 
  • Acute allergic symptoms are caused by allergen-induced crosslinking of allergen-specific immunoglobulin E (IgE) bound to Fc-epsilon receptors on effector cells. Desensitization with allergen-specific immunotherapy (SIT) has been used for over a centu ...

    Acute allergic symptoms are caused by allergen-induced crosslinking of allergen-specific immunoglobulin E (IgE) bound to Fc-epsilon receptors on effector cells. Desensitization with allergen-specific immunotherapy (SIT) has been used for over a century, but the dominant protective mechanism remains unclear. One consistent observation is increased allergen-specific IgG, thought to competitively block allergen binding to IgE. Here we show that the blocking potency of the IgG response to Cat-SIT is heterogeneous. Next, using two potent, pre-selected allergen-blocking monoclonal IgG antibodies against the immunodominant cat allergen Fel d 1, we demonstrate that increasing the IgG/IgE ratio reduces the allergic response in mice and in cat-allergic patients: a single dose of blocking IgG reduces clinical symptoms in response to nasal provocation (ANCOVA, pā€‰=ā€‰0.0003), with a magnitude observed at day 8 similar to that reported with years of conventional SIT. This study suggests that simply augmenting the blocking IgG/IgE ratio may reverse allergy.


    Organizational Affiliation

    Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA. jamie.orengo@regeneron.com.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Antibody light chain
L, A
214N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Antibody Fab heavy chain
H, B
220N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
Chimera of Major allergen I polypeptide chain 2,Major allergen I polypeptide chain 1
F, C
199Felis catusMutation(s): 1 
Gene Names: CH2, CH1
Find proteins for P30440 (Felis catus)
Go to UniProtKB:  P30440
Find proteins for P30438 (Felis catus)
Go to UniProtKB:  P30438
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
CA
Query on CA

Download SDF File 
Download CCD File 
C, F
CALCIUM ION
Ca
BHPQYMZQTOCNFJ-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.9 Å
  • R-Value Free: 0.259 
  • R-Value Work: 0.225 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 74.985α = 90.00
b = 131.480β = 90.00
c = 148.357γ = 90.00
Software Package:
Software NamePurpose
REFMACrefinement
HKL-2000data scaling
PHASERphasing
HKL-2000data reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2017-05-25 
  • Released Date: 2018-04-04 
  • Deposition Author(s): Franklin, M.C.

Revision History 

  • Version 1.0: 2018-04-04
    Type: Initial release
  • Version 1.1: 2018-12-05
    Type: Data collection, Database references